Company Updates
Champions Oncology names Robert Brainin chief executive officer
Champions Oncology said on July 18, 2025 that its board appointed director Robert Brainin as chief executive, effective August 25, 2025, succeeding Ronnie Morris, M.D., who becomes executive chair.

Champions Oncology, Inc. (Nasdaq: CSBR) said on July 18, 2025 that its board had appointed Robert Brainin as chief executive officer, effective August 25, 2025. Brainin has served on the board since February 2021. The company reported the appointment in a Form 8-K filed July 21, 2025, which also files his employment agreement, dated effective July 16, 2025.
Why is this important: Champions is a contract research business for oncology drugs, and its chief executive has been Ronnie Morris since 2017. The change puts a former Veracyte and Genuity Science executive in charge of a company whose 10-Q for the quarter ended January 31, 2025 reports cash and cash equivalents of $3,202 thousand. Holders now depend on the new chief executive to make the company's data strategy pay.
Ronnie Morris, M.D., leads the company as chief executive until August 25, 2025 and then becomes executive chair. Joel Ackerman, the chairman, said in the release: "Rob’s expertise and track record of driving growth in innovative life sciences businesses make him the ideal leader to guide Champions through its next chapter." In our view, this is the first change at the top since 2017, and the release sets no timetable for when the data business must show results.
Who Brainin is and what the filing says
The 8-K describes Brainin as having more than 25 years of experience in life sciences and technology. He was most recently Chief Business Officer and Executive Vice President at Veracyte, an oncology diagnostics company, from July 2021. From August 2017 to January 2021 he worked at Genuity Science, where he held several positions, including chief executive, chief operating officer and director.
The filing states that Brainin will remain a director after he becomes chief executive. The release says Ackerman transitions from chairman to a director role, and the 8-K was signed by Ackerman in his capacity as chairman of the board of directors.
Brainin's own words in the release tie the appointment to the core business. He said: "The strength of Champions’ core CRO services provides a tremendous foundation to expand our emerging data platform and advance the pipeline of our discovery therapeutics subsidiary, Corellia AI."
The science and the business the new chief inherits
Champions describes its platform as the largest and most annotated bank of clinically relevant patient-derived xenograft, or PDX, and primary hematological malignancy models. The company sells research services built on those models. It also offers Lumin Bioinformatics, an oncology data-driven software-as-a-service program that the 10-Q describes as using analytics and artificial intelligence. The press release calls the company a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing. Its discovery subsidiary is Corellia AI.
The filings cited name no clinical trial and no ClinicalTrials.gov number for a Champions drug. The filings say the company's studies "can simulate the results of human clinical trials". That is a claim about the company's models, not a clinical result, and this story treats it that way.
The Form 10-Q for the quarter ended January 31, 2025 reports cash and cash equivalents of $3,202 thousand at January 31, 2025, against $2,618 thousand at April 30, 2024. Oncology revenue for the nine months was $44,589 thousand, up from $36,153 thousand. Net income for the nine months was $6,536 thousand, against a net loss of $7,167 thousand a year earlier.
What comes next
The appointment takes effect on August 25, 2025. Until then, Morris remains chief executive. The 8-K files the employment agreement as Exhibit 10.1 to the report. The release says Morris will support the leadership transition while remaining actively involved in the company's strategic initiatives, and Ackerman said Morris will keep an active role as executive chair.
The company says its strategy is to expand beyond its core CRO services into data. Shareholders should watch whether that expansion begins to appear in reported revenue, and whether Brainin's first results show the data business as a separate line of growth or only a supporting one.
Investor Chat
Loading posts…
aibio